Article

Alcon, Advanced Medical Optics enter into IOL patent agreement

Huenenberg, Switzerland-Alcon Inc. and Advanced Medical Optics (AMO) have entered into a patent cross-licensing agreement relating to a specified one-piece IOL design and lubricious coatings for IOL insertion devices.

Huenenberg, Switzerland-Alcon Inc. and Advanced Medical Optics (AMO) have entered into a patent cross-licensing agreement relating to a specified one-piece IOL design and lubricious coatings for IOL insertion devices.

The agreement provides AMO with paid-up, non-exclusive, worldwide licenses restricted to single-piece IOLs having the same design as AMO’s recently launched IOL (Tecnis), according to a prepared statement issued by Alcon. The licenses assure AMO of freedom to operate with respect to the subject Alcon patents, relative to the launched IOL and any future IOL models having the same design platform. AMO will pay Alcon a lump sum of $10 million for those licenses, according to Alcon.

Additionally, Alcon will receive paid-up, non-exclusive, worldwide licenses under two families of patents owned by AMO, according to the statement. The licenses assure Alcon of freedom to operate with respect to the two patents, relative to the coating systems currently used in its IOL insertion devices (Monarch and AcrySert), as well as any future coating systems of a similar type that Alcon may develop. In the statement, Alcon said it will pay AMO a lump sum of $31 million for those licenses.

Other terms of the agreement were not disclosed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.